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A r t i c l e s effects: mercaptopurine can be directly anabolized by thiopurine methyltransferase (TPMT) to the inactive methylmercaptopurine, and thiopurine active metabolites can also be catabolized via dephosphorylation of thioguanine nucleotides (TGN) 32, 33 . Therefore, thiopurine cytotoxicity is determined by competition between the activation and inactivation pathways, the components of which are affected by genetic variations. In particular, SNPs in the TPMT gene have been shown to cause loss of TPMT enzymatic activity and excessive levels of TGN and to predispose patients to thiopurinerelated hematopoietic toxicity across multiple diseases 23, [34] [35] [36] [37] [38] . In fact, TPMT-guided preemptive thiopurine dose adjustment has been shown to substantially reduce the risk of adverse effects without compromising therapeutic efficacy [39] [40] [41] [42] [43] [44] [45] and is a prototype of precision medicine approaches to individualize drug therapy based on pharmacogenetics. However, substantial toxicity still occurs in some patients with normal TPMT activity, suggesting that additional variables, including other genetic variants, may contribute to the between-patient variability in thiopurine metabolism.
Recent genome-wide association studies described a missense variant in the NUDT15 gene (rs116855232, referred to as c. 415C>T or p.Arg139Cys hereafter) that is strongly associated with thiopurine-related myelosuppression in patients with IBD 46 and in children with ALL 47 . Individuals homozygous for the risk allele encoding p.Arg139Cys were exquisitely sensitive to mercaptopurine and tolerated only 8% of the standard dose, and this NUDT15 variant alone explained 22% of variance in mercaptopurine tolerance 47 . Constituting a purported purine-specific nucleotide diphosphatase, NUDT15 is hypothesized to dephosphorylate the thiopurine active metabolites TGTP and TdGTP, thus preventing their incorporation into DNA and negatively affecting the desired cytotoxic effects of thiopurines. However, the exact mechanism by which NUDT15 regulates thiopurine metabolism has not been experimentally examined, and the functional consequences of NUDT15 variants are unknown.
In this study, we systematically identified NUDT15 variants associated with thiopurine disposition and host toxicity, characterized the enzymatic properties of the corresponding proteins and comprehensively investigated the molecular pathways linking NUDT15 to thiopurine toxicity. Our results suggest that a comprehensive pharmacogenetic model integrating NUDT15 genetic variants may inform strategies to further individualize thiopurine therapy.
RESULTS
NUDT15 variant discovery and function characterization
To systematically characterize NUDT15 polymorphisms associated with thiopurine toxicity, we sequenced all exonic regions of this gene in three cohorts comprising 270 children treated on frontline ALL clinical trials in Guatemala, Singapore and Japan (Supplementary Table 1 ). In total, we identified four coding variants located in exons 1 and 3, all of which resulted in changes in the amino acid sequence of the NUDT15 protein (Fig. 1a) . The c.415C>T and c.416G>A variants were transition substitutions within the codon for residue Arg139, causing an arginine-to-cysteine and arginine-to-histidine change (p.Arg139Cys and p.Arg139His), respectively. The other two variants affected the Val18 residue: c.52G>A resulted in a valine-to-isoleucine substitution (p.Val18Ile), and c.36_37insGGAGTC led to an in-frame addition of a glycine and a valine residue (p.Val18_Val19insGlyVal). We inferred five NUDT15 haplotypes with distinct combinations of genotypes at these four variants (referred to as haplotypes *1-*5 hereafter; Fig. 1a) . In particular, the p.Val18_Val19insGlyVal allele was in high linkage disequilibrium (LD) with the p.Arg139Cys allele, and the presence of both variants defined the common haplotype *2. Analyses of phased 1000 Genomes Project data identified similar haplotype patterns, and the prevalence of each haplotype varied substantially by ancestry (Supplementary Fig. 1) .
To define the functional consequences of the NUDT15 polymorphisms, we characterized nucleotide diphosphatase activity for each of the four variant proteins (Fig. 1b) . Wild-type NUDT15 efficiently converted the thiopurine active metabolite TGTP to the monophosphate thioguanosine nucleotide TGMP, with an apparent catalytic efficiency (V max /K m , ratio of maximal velocity to Michaelis constant) of 107.9 ± 0.2. In contrast, the four variant NUDT15 proteins showed 74.4 to 100% loss of enzymatic activity, with V max /K m of 23.6 ± 0.9, 27.7 ± 1.1 and 14.9 ± 1.1 for the Arg139His, Val18Ile and Val18_Val19insGlyVal variants, respectively; enzymatic activity was not detectable for the Arg139Cys or Val18_Val19insGlyVal/Arg139Cys variant protein. We observed similar differences in NUDT15 activity when TdGTP was used as the substrate (Supplementary Fig. 2 ). Although p.Arg139Cys and p.Val18_Val19insGlyVal individually caused a reduction in NUDT15 activity, the protein harboring both variants did not show further loss of function as compared to the protein with p.Arg139Cys alone (Fig. 1b) , suggesting that haplotype *2 is likely to have similar functional consequences as haplotypes with a single variant (for example, *3). A thermostability assay showed substantially lower T m (protein unfolding temperature) values for all variant NUDT15 proteins (42.6 ± 0.1 °C, 43.6 ± 0.2 °C, 52.5 ± 0.3 °C, 41.5 ± 0.1 °C and 54.0 ± 0.1 °C for Arg139Cys, Arg139His, Val18Ile, Val18_Val19insGlyVal/Arg139Cys and Val18_Val19insGlyVal, respectively) as compared to the wildtype protein (56.3 ± 0.3 °C), consistent with perturbation of NUDT15 conformation by the substitutions (Supplementary Fig. 3 ). 
A r t i c l e s
Further, we tested different combinations of variant NUDT15 proteins to determine enzymatic activity for each of the eight diplotypes observed in our clinical cohorts (Fig. 1c) . Equimolar mixtures of variant and wild-type NUDT15 proteins (the equivalent of patients heterozygous at a single variant, for example, *1/*3) showed intermediate activity, indicating a gene dosage effect. In comparison, the mixture of two different variant NUDT15 proteins (for example, *3/*5) resulted in low activity that was comparable to that for a single variant with the same total protein concentration (for example, *3/*3), suggesting that individuals with compound-heterozygous genotypes are likely to have similar mercaptopurine intolerance as those homozygous for a single NUDT15 variant. Therefore, we classified patients into three diplotypic groups (Fig. 1c) : normal activity (*1/*1), intermediate activity (*1/*2, *1/*3, *1/*4 and *1/*5) and low activity (*2/*3, *3/*3 and *3/*5). There were no significant differences in enzymatic activity between diplotypes within the intermediate-activity group (P = 0.73) or within the low-activity group (P = 0.19).
Consistently in the Guatemalan, Singaporean and Japanese cohorts (n = 159, 79 and 32, respectively), mercaptopurine tolerance was highest in patients with the normal-activity NUDT15 diplotype, followed by those with intermediate activity, and was lowest in patients with the diplotypes indicative of low NUDT15 activity (P = 0.021, 2.1 × 10 −5 and 0.0054, respectively; Fig. 2 ). Of particular note, patients with the *1/*2 diplotype (heterozygous at both p.Arg139Cys and p.Val18_Val19insGlyVal) showed a similar degree of mercaptopurine intolerance as the *1/*3 group (heterozygous at the p.Arg139Cys variant alone; Supplementary Fig. 4 ), corroborating our observation that single-variant (Arg139Cys) and double-variant (Val18_Val19insGlyVal/Arg139Cys) NUDT15 proteins exhibit similar enzymatic activity (Fig. 1b) . Additionally, two patients with compound-heterozygous NUDT15 genotypes (*3/*5 and *2/*3) were exquisitely sensitive to mercaptopurine, with sensitivities on the same scale as for patients homozygous for the variant allele (*3/*3), indicating cumulative effects for the NUDT15 variants ( Supplementary Fig. 4) . A meta-analysis combining the three cohorts indicated strong and consistent effects of NUDT15 variants on tolerated mercaptopurine dosage (P = 4.45 × 10 −8 , allelic effect size of −11.5 (95% confidence interval, −15.6 to −7.4); Fig. 2d ), and we did not observe any statistically significant heterogeneity across the cohorts (P = 0.34). Including patients with non-functional variants in TPMT (rs1800462, rs1800460 and rs1142345) had minimal effects on the association of NUDT15 diplotype with tolerated mercaptopurine dosage (meta-analysis P = 9.96 × 10 −10 and 9.92 × 10 −8 for before and after adjusting for TPMT variants, respectively; Supplementary Fig. 5 ), indicating independent contributions of these two genes to mercaptopurine metabolism and toxicity.
NUDT15 regulates thiopurine activation and cytotoxicity
Because NUDT15 converts TGTP to TGMP (and TdGTP to TdGMP), we hypothesized that NUDT15 prevents the incorporation of these thiopurine metabolites into DNA (DNA-TG) and negatively regulates thiopurine activation and, consequently, cytotoxicity. To recapitulate the loss of NUDT15 activity resulting from genetic variation, we first established stable NUDT15 knockdown in a human lymphoid cell line (Supplementary Fig. 6 ). In control cells transduced with scrambled short hairpin RNA (shRNA), mercaptopurine was extensively (Fig. 3a) . Consequently, DNA-TG levels were markedly higher in NUDT15-knockdown cells than in control cells (8,219.9 ± 853.6 fmol/µg DNA and 1,734.7 ± 25.7 fmol/µg DNA, respectively; Fig. 3b ), leading to an increase in mercaptopurine-induced apoptosis in these cells ( Fig. 3c and Supplementary  Fig. 7a ). With increasing concentrations of mercaptopurine, there was concomitant elevation of intracellular DNA-TG levels, and the rate at which mercaptopurine was incorporated into DNA was greater in the NUDT15-knockdown cells than in control cells (Fig. 3d) . Similarly, when we repeated these experiments with thioguanine or azathioprine, the NUDT15-knockdown cells consistently showed increased levels of active metabolites (for example, TGTP and DNA-TG) and higher susceptibility to thioguanine-or azathioprine-induced apoptosis (Fig. 3e-h and Supplementary Figs. 7b  and 8) . Together, these results indicate that NUDT15 inactivates thiopurine metabolites and is directly related to their cytotoxic effects, thus providing a clear biological mechanism explaining the susceptibility to thiopurine host toxicity in patients inheriting loss-ofactivity variants in NUDT15.
NUDT15 variants and thiopurine metabolism in vivo
Building upon the in vitro results, we next sought to determine how inherited NUDT15 deficiency influences thiopurine activation in patients by directly monitoring DNA-TG levels in white blood cells from children with ALL receiving daily mercaptopurine treatment. In 32 patients in the Singaporean cohort, DNA-TG levels strongly correlated with the actual mercaptopurine dosage delivered (P = 0.0024; Fig. 4a ). The positive correlation between mercaptopurine dosage and DNA-TG levels was also validated in the Japanese cohort (n = 32, P = 2.2 × 10 −4 ; Fig. 4b ). The ratio of DNA-TG levels to mercaptopurine dosage (the amount of DNA-TG converted from every unit mercaptopurine dose) varied significantly by NUDT15 genotype. In the Singaporean cohort ( Fig. 4c and Supplementary Fig. 9a ), the average DNA-TG to mercaptopurine dosage ratio was 6.0 ± 2.7 fmol/µg DNA/mg mercaptopurine in children with wild-type NUDT15 (*1/*1). In contrast, children with intermediate-activity npg mercaptopurine; P = 7.7 × 10 −5 ). Similarly, in the Japanese cohort ( Fig. 4d and Supplementary Fig. 9b ), the DNA-TG to mercaptopurine dosage ratio was 9.6 ± 4.1, 12.3 ± 4.5 and 32.4 fmol/µg DNA/mg mercaptopurine for children with normal-, intermediate-and low-activity NUDT15 diplotypes, respectively (P = 2.9 × 10 −4 ). A meta-analysis combining the Singaporean and Japanese cohorts indicated strong and consistent association of NUDT15 diplotype with normalized DNA-TG levels (P = 2.2 × 10 −8 ), and we did not observe significant heterogeneity between the cohorts (P = 0.63).
DISCUSSION
The current study has comprehensively characterized the effects of inherited variants of NUDT15 on the metabolism of thiopurine and on the clinical tolerance of thiopurine toxicity. These new findings are important for multiple reasons. First, these NUDT15 variants are highly penetrant and confer exquisite sensitivity to thiopurines (homozygous carriers can tolerate <10% of the standard dosage), with effect sizes comparable to those of the TPMT variants that are clinically implemented to guide thiopurine dose reduction 46, 47 .
In fact, in a multiethnic cohort of children with ALL, the NUDT15 variant encoding p.Arg139Cys alone explained 22% of variance in mercaptopurine tolerance 47 . Second, TPMT variants are generally rare among Asian populations 48 and are thus of limited relevance for guiding thiopurine dosing in these ancestral groups. In contrast, NUDT15 genetic variation is substantially over-represented in Asians and is the predominant genetic cause in this population of thiopurine toxicity 46, 47 A critical barrier to integrating NUDT15 genotypes into the thiopurine dosing algorithm has been the paucity of data to establish the pharmacological basis for dose reduction for patients with NUDT15 risk alleles. Addressing this knowledge gap, our results from a variety of laboratory model systems and in patients collectively indicate that NUDT15 deficiency directly results in excessive levels of thiopurine active metabolites (TGTP and DNA-TG) and increased host toxicity. Therefore, reducing thiopurine doses for patients who carry the NUDT15 variants would likely tailor their exposure to levels of TGTP and DNA-TG that are similar to those in patients with wildtype NUDT15 receiving standard thiopurine doses. This is a highly plausible strategy for using NUDT15 genotype to individualize thiopurine therapy to mitigate toxicity, as it is the same principle used for the TPMT-based dose adjustments already implemented clinically 51 . In fact, in 285 children with newly diagnosed ALL, leukemic cells with intermediate-activity NUDT15 diplotypes were also significantly more sensitive to thioguanine than those with the wild-type diplotype (P = 0.03; Supplementary Fig. 10) . Therefore, genotype-guided thiopurine dose reductions in patients with ALL inheriting NUDT15 risk alleles would likely minimize side effects without compromising antileukemic efficacy. Future clinical studies will be needed to precisely define the optimal dosage of thiopurines in patients with different NUDT15 diplotypes. The strength of the association between NUDT15 variants and tolerated mercaptopurine dosage also differed slightly among three ALL cohorts (strongest in Singaporeans and weakest in Guatemalans; Fig. 2 ). Among these three populations, Guatemalans had the lowest tolerated mercaptopurine dosage even with wild-type NUDT15 and had smaller differences in mercaptopurine tolerance across the NUDT15 genotype groups (although the differences were still significant). It is possible that other (as yet unknown) genetic variants associated with thiopurine toxicity exist uniquely in Guatemalans, potentially contributing to the overall sensitivity of the population to this class of drugs. These hypotheses should be examined in future studies.
Our targeted sequencing of NUDT15 identified four coding variants, all of which influenced NUDT15 activity and were linked to thiopurine toxicity (Figs. 1 and 2) . Intriguingly, two of these variants both affect residue Arg139 that is located in the a2 α helix at the base of the NUDT15 substrate-binding pocket 52 . It has been hypothesized that the substitution of arginine with cysteine at this position (p.Arg139Cys) might introduce a disulfide bond and, thus, structural perturbation that interferes with TGTP binding 52 . In contrast, the arginine-to-histidine change caused by the p.Arg139His variant might lead to reduced electrophilicity and compromise substrate interaction. The other two NUDT15 variants affect residue Val18 within the β sheet at the N terminus of the protein; it is unclear how the substitution and insertion at this position structurally hinder NUDT15 function. It is also possible that coding variants can affect NUDT15 protein synthesis and/or degradation and thus indirectly influence enzymatic activity, as we have shown for TPMT variants 53 . However, when ectopically expressed in HEK293T cells, the NUDT15 variants identified herein showed relatively high protein stability over time in vitro, with stability comparable to that of wild-type NUDT15 ( Supplementary Fig. 11 ); it will be important to document a similar lack of differences in patients with the corresponding NUDT15 genotypes.
It was originally believed that NUDT15 functions as a sanitizer to remove damaged nucleotides, for example, the oxo-dGTP generated from radical oxygen species 54 . However, this hypothesis has been challenged by more recent data showing a strong preference of NUDT15 for thiopurine metabolites over oxo-dGTP 52 . NUDT15 has also been shown to efficiently hydrolyze dGTP, with potential importance in purine nucleotide homeostasis 52 , but its exact physiological functions remain unknown. It is unclear whether lossof-function NUDT15 variants confer susceptibility to any diseases, although there is no evidence in the literature to suggest that this is the case. It is plausible that NUDT15 deficiency has limited effects on endogenous nucleotide metabolism under normal physiological conditions because of compensation by other NUDT proteins with overlapping enzymatic functions 52, 55 . In contrast, the prominent role of NUDT15 in thiopurine inactivation signifies the potential importance of the NUDT family of enzymes in the metabolism of other nucleotide analog drugs, which are widely used for diverse human diseases (especially in antiviral therapy) 56 . Therefore, the comprehensive identification of pharmacogenetic variants in NUDT genes may have broad clinical relevance.
Our results from comprehensive in vitro and in vivo studies strongly indicate that NUDT15-related thiopurine toxicity follows an additive genetic mode of inheritance, with the severity of the phenotype proportional to the cumulative number of risk alleles in NUDT15. Patients homozygous or compound heterozygous for NUDT15 risk alleles experience especially excessive mercaptopurine toxicity, as compared to those with intermediate-or normal-activity diplotypes (Fig. 2) . This is not unexpected because homozygous-variant NUDT15 protein is enzymatically inactive (Fig. 1c) , and complete loss of this important metabolizing enzyme results in disproportionally high levels of active metabolite and thus toxicity, as also seen in patients with inherited TPMT deficiency 12, 35 . The interpretation of NUDT15 genotype becomes more complicated when a patient carries multiple functional variants. For example, if two variants are on the same haplotype, the patient is likely to have intermediate NUDT15 activity npg A r t i c l e s because the remaining wild-type copy is still functional (for example, *1/*2). In contrast, if each of these two variants affects a different copy of NUDT15 (compound heterozygous; for example, *3/*5), enzymatic activity is completely lost in these patients, similarly to in subjects with a homozygous-variant genotype (for example, *3/*3). These two scenarios indicate distinct levels of thiopurine tolerance and can be distinguished only through haplotype-based analyses. Using phased sequencing data from the 1000 Genomes Project, we inferred NUDT15 diplotypes in major ancestral groups worldwide (Supplementary Fig. 1 ) and experimentally determined the enzymatic activity corresponding to each haplotype. NUDT15 deficiency (from low-or intermediateactivity diplotypes) was most common in East Asians (22.6%) and was also prevalent in South Asians (evenly distributed in India, Pakistan, Bangladesh and Sri Lanka at 13.6%) and Native American populations (for example, 21.2% in Peruvians and 12.5% in Mexicans). In fact, in our Japanese cohort, approximately one in every three individuals carried risk variant(s) in the NUDT15 gene, a frequency that is even higher than that of TPMT deficiency (for example, one in every 12 Europeans and one in every eight Africans) 51 . We have also identified rare NUDT15 variants in the Broad Institute Exome Aggregation Consortium data set derived from whole-exome sequencing of 60,706 individuals (Supplementary Table 2) , although the function of these variants and their effects on thiopurine metabolism are unknown.
As previously described 47 , cases with variants in both NUDT15 and TPMT were significantly less tolerant of mercaptopurine than those with risk alleles in only one of these two genes. Therefore, integration of NUDT15 variants in the thiopurine dosing algorithm may have major implications for Asian populations, whereas TPMT variants are most informative for thiopurine toxicity in Europeans and Africans. A polygenic dosing algorithm that incorporates both NUDT15 and TPMT variants would potentially provide a robust approach to personalize thiopurine therapy in major ancestral groups represented in diverse populations worldwide.
URLs. Japanese Pediatric Leukemia/Lymphoma Study Group ALL-B12 (UMIN000009339), http://www.umin.ac.jp/; R version 3.0, http://www.r-project.org/; 1000 Genomes Project, http:// www.1000genomes.org/; Broad Institute Exome Aggregation Consortium, http://exac.broadinstitute.org/.
METHODS
Methods and any associated references are available in the online version of the paper. NUDT15 sequencing and TPMT genotyping. The coding regions (exons 1-3) of the NUDT15 gene were first amplified by PCR from germline DNA, followed by Sanger sequencing (primer sequences are provided in Supplementary  Table 3) . Sequence alignment and comparison were performed using the CLC Genomics Workbench (CLC Bio, Qiagen) to identify genetic variants. NUDT15 variant genotype was coded as 0, 1 or 2 to indicate the number of variant alleles, and the sequencing data were analyzed using PHASE 59 to infer haplotypes. TPMT variants (rs1800462, rs1800460 and rs1142345) were manually genotyped as described previously 60 for all patients, and individuals with variant genotypes (n = 20 and 2 in the Guatemalan and Singaporean cohorts, respectively) were excluded from subsequent analyses unless otherwise indicated.
NUDT15 purification, enzymatic activity measurement and thermostability assay. Human NUDT15 cDNA (BC133017) was cloned into the pCold II expression vector (TaKaRa Bio) with a sequence encoding an N-terminal His tag, as previously described 54 . Missense and insertion variants (p.Arg139Cys, p.Arg139His, p.Val18Ile, p.Val18_Val19insGlyVal and p.Val18_Val19insGlyVal/p.Arg139Cys) were introduced by site-directed mutagenesis using the QuikChange II XL kit (Agilent Technologies). Wild-type or variant NUDT15 protein was ectopically expressed in E. coli BL21 with isopropyl β-d-1-thiogalactopyranoside (IPTG) induction (0.5 mM, 24 h at 15 °C) and purified by affinity chromatography using TALON metal affinity resin (Clontech). Purified proteins were concentrated with an Amicon Ultra 0.5-ml centrifugal filter (Sigma-Aldrich) in 10 mM pH 8.0 Tris-HCl buffer containing 0.1 mM EDTA, 5 mM DTT and 10% glycerol. Protein purity was determined by SDS-PAGE and Coomassie blue staining ( Supplementary  Fig. 12) , and the molecular weight of each NUDT15 protein was confirmed by time-of-flight mass spectrometry using the Waters LCT Premier XE MS (Supplementary Table 4) .
NUDT15 diphosphatase activity was measured by quantifying the release of pyrophosphate using the PiPer Pyrophosphate Assay kit (Life Technologies). Each NUDT15 protein (100 ng) was incubated with varying concentrations of TGTP (1.88 to 21.4 µM) or TdGTP (0.99 to 35.7 µM) at 37 °C for 10 min before heat inactivation (99 °C for 20 min). Free pyrophosphate was then immediately quantified by fluorescence spectrometry according to the manufacturer's instructions, and K m and V max values were determined by Michaelis-Menten kinetics methods in Prism (GraphPad). Each experiment was carried out in triplicate and was repeated at least three times.
To determine protein thermostability, 1 µg of wild-type or variant NUDT15 protein was incubated with 10× SYPRO Orange (Molecular Probes), and the mixture was heated from 20 °C to 95 °C in increments of 0.2 °C in the QuantStudio 12K Flex RT-PCR system (Applied Biosystems). Changes in fluorescence were monitored with a charge-coupled device camera, with excitation and emission wavelengths at 490 nm and 575 nm, respectively. T m values, the temperature midpoint for the protein unfolding transition, were calculated on the basis of the Boltzmann model in Prism.
To assess NUDT15 protein stability in vitro, variant or wild-type NUDT15 cDNA encoding protein with an N-terminal FLAG tag in the pcDNA3.1 backbone (Invitrogen) was transiently expressed in HEK293T cells (American Type Culture Collection) using polyethylenimine reagent (Polysciences). Cycloheximide (50 µg/ml) was added 48 h after transfection, and NUDT15 protein levels were monitored after 0, 24 and 48 h by immunoblot analysis with β-actin as the loading control (antibody to FLAG, 2368, Cell Signaling Technology; 1:5,000 dilution).
NUDT15 knockdown and thiopurine metabolism in vitro. Lentiviral vectors containing shRNAs specific for human NUDT15 (TRCN0000050311) or scrambled sequence (SHC016) were purchased from Sigma-Aldrich. Viral particles were prepared using the calcium chloride method in HEK293T cells, and stable knockdown was established in the NALM-6 human lymphoid cell line (German Collection of Microorganisms and Cell Cultures, DSMZ) by lentiviral transduction of shRNA and puromycin selection, following procedures described previously 61 . Cell lines were authenticated by karyotyping and cytogenetics and tested negative for mycoplasma contamination. The level of NUDT15 knockdown was determined by real-time quantitative PCR with human tubulin as the internal control (Supplementary Fig. 6a ; primer sequences are provided in Supplementary Table 3 ). NUDT15 expression was also determined at the protein level by immunoblot analysis with β-actin as the loading control (antibody to NUDT15, ab122521, Abcam, 1:500 dilution; Supplementary Fig. 6b) .
To determine thiopurine metabolism in vitro, 5 × 10 6 NUDT15-knockdown or control cells were treated with varying concentrations of mercaptopurine or thioguanine at 37 °C for 48 h. Cytosolic thiopurine metabolites (for example, TGTP, TGDP and TGMP) were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) according to a previously reported method 62 . In parallel, aliquots of mercaptopurine-, thioguanine-or azathioprine-treated cells were processed to extract genomic DNA, and DNA-TG level was measured using LC-MS/MS as described previously 63 . Mercaptopurine, thioguanine and azathioprine cytotoxicity was determined for NUDT15-knockdown and control cells using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay at the end of the 72-h period of drug exposure. In vitro experiments were carried out in triplicate and were repeated at least three times.
Thiopurine metabolism in children with ALL. To investigate in vivo thiopurine metabolism, DNA incorporation of TdGTP (the level of DNA-TG) was longitudinally monitored during the maintenance therapy phase in a subset of children enrolled on the MaSpore ALL 2010 and JPLSG ALL-B12 protocols. In the Singaporean cohort (n = 32), peripheral blood was collected every 3 months during maintenance, with a maximum of 3, 4 and 5 time points for those on the high-, intermediate-and standard-risk arms, respectively. In the Japanese cohort (n = 32), peripheral blood collection was scheduled at weeks 13 and 41 of maintenance therapy. For both cohorts, genomic DNA was extracted from leukocytes within 72 h of blood draw, and DNA-TG level was quantified using LC-MS/MS as described previously 63 ; a detailed mercaptopurine dosing history was recorded for 14 d before each sample collection.
To examine the effects of NUDT15 variants on leukemic cell sensitivity to thiopurine, we also evaluated thiopurine LC 50 (the drug concentration that is lethal to 50% of cells) in 285 children with newly diagnosed ALL. Primary ALL cells were exposed to increasing concentrations of thioguanine for 96 h, npg
